Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

JERSEY CITY, N.J., DEC. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT IT HAS RECEIVED AN ADDITIONAL 180-CALENDAR-DAY EXTENSION FROM THENASDAQ STOCK MARKET(NASDAQ) TO REGAIN COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT, AS OUTLINED IN NASDAQ LISTING RULE 5550(A)(2).

SCYNEXIS GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT

JERSEY CITY, N.J., NOV. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT IT HAS COMPLETED THE TRANSFER OF THE BREXAFEMME (IBREXAFUNGERP) NEW DRUG APPLICATION (NDA) TO GSK.

SCYNEXIS COMPLETES TRANSFER OF BREXAFEMME NEW DRUG APPLICATION TO GSK

JERSEY CITY, N.J., NOV. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ:SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

SCYNEXIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., OCT. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT IT WILL RECEIVE A $22 MILLION PAYMENT FROM GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED (GSK) AS PART OF A RESOLUTION OF THE DISAGREEMENT WITH GSK RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY ON INVASIVE CANDIDIASIS. SCYNEXIS WILL NOT RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM GSK ASSOCIATED WITH THE MARIO STUDY. SCYNEXIS WILL PROMPTLY COMMENCE APPROPRIATE WIND-DOWN ACTIVITIES ASSOCIATED WITH ITS TERMINATION AND WILL RECEIVE AN ADDITIONAL $2.3M PAYMENT IN CONNECTION WITH THESE ACTIVITIES.

SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY

JERSEY CITY, N.J., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED MULTIPLE UPCOMING PRESENTATIONS HIGHLIGHTING DATA ON THE COMPANY'S SECOND-GENERATION FUNGERP DRUG CANDIDATE, SCY-247, AT THE UPCOMING 12TH CONGRESS ON TRENDS IN MEDICAL MYCOLOGY (TIMM-12), WHICH IS SCHEDULED TO TAKE PLACE FROM SEPTEMBER 19TH TO 22ND, 2025, IN BILBAO, SPAIN.

SCYNEXIS ANNOUNCES MULTIPLE PRESENTATIONS HIGHLIGHTING DATA FROM ITS SECOND-GENERATION FUNGERP, SCY-247, AT THE 12TH CONGRESS ON TRENDS IN MEDICAL MYCOLOGY (TIMM-12)

JERSEY CITY, N.J., AUG. 13, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

SCYNEXIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., MAY 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED THAT PATIENT DOSING HAS RESUMED IN THE PHASE 3 MARIO STUDY, WHICH IS AN INNOVATIVE STUDY TO INVESTIGATE ORAL IBREXAFUNGERP AS A POTENTIAL STEP-DOWN ANTIFUNGAL THERAPY FOLLOWING IV ECHINOCANDIN FOR INVASIVE CANDIDIASIS, A LIFE-THREATENING INFECTION. THE STUDY HAD BEEN ON HOLD DUE TO CONCERNS ABOUT POTENTIAL CROSS-CONTAMINATION IN LIGHT OF DRAFT U.S. FOOD AND DRUG ADMINISTRATION (FDA) GUIDANCE REGARDING MANUFACTURING A NON-ANTIBIOTIC BETA-LACTAM (EZETIMIBE) AT THE SAME SITE AS IBREXAFUNGERP. THE STUDY HAS RESUMED FOLLOWING THE MANUFACTURE OF NEW CLINICAL SUPPLIES AT ANOTHER SITE AND THE LIFTING OF THE CLINICAL HOLD BY THE FDA. IF THE STUDY IS SUCCESSFUL AND APPROVAL FOR THIS INDICATION IS GRANTED BY THE FDA, IT WILL GIVE HEALTHCARE PROVIDERS THE OPPORTUNITY TO STEP-DOWN THEIR PATIENTS TO A NON-AZOLE ORAL THERAPY THAT RETAINS THE MECHANISM OF ACTION (GLUCAN SYNTHASE INHIBITION) OF THE IV-ONLY ECHINOCANDINS, WHICH ARE THE GOLD STANDARD FOR TREATMENT OFINVASIVE CANDIDAINFECTIONS. SCYNEXIS'S POSITION IS THAT THE DOSING OF THIS FIRST NEW PATIENT TRIGGERS A $10 MILLION PAYMENT FROM PARTNER GSK, WITH ANOTHER $20 MILLION PAYMENT TO BE TRIGGERED BY THE SIX-MONTH ANNIVERSARY OF DOSING.AS PREVIOUSLY DISCLOSED, THERE IS A DISAGREEMENT BETWEEN SCYNEXIS AND GSK REGARDING THE RESUMPTION OF THE MARIO STUDY AND GSK'S RESPONSIBILITY FOR PAYING THESE MILESTONES. SCYNEXIS IS WORKING TO RESOLVE THE DISAGREEMENT.

SCYNEXIS RESUMES PATIENT DOSING IN PHASE 3 MARIO STUDY

JERSEY CITY, N.J., MARCH 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024.

SCYNEXIS REPORTS FULL YEAR 2024 FINANCIAL RESULTSAND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., NOV. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024.

SCYNEXIS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERSEY CITY, N.J., OCT. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, INC. (NASDAQ: SCYX), A BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE MEDICINES TO OVERCOME AND PREVENT DIFFICULT-TO-TREAT AND DRUG-RESISTANT INFECTIONS, TODAY ANNOUNCED DAVID ANGULO, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2024 MAXIM HEALTHCARE VIRTUAL SUMMIT ON THURSDAY, OCTOBER 17, AT 11:30 A.M. ET.

SCYNEXIS, Inc.

SCYX

Price

Financial Reports

No items found.

Press Releases

SCYNEXIS, Inc.

SCYX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SCYX